The March 2026 NHS England Board papers show that elective recovery is moving in the right direction, but not yet on secure footing. 

The total elective waiting list has reduced. Long waits are falling. The under-18 waiting list is lower than a year earlier. Referral to Treatment performance has improved compared with January 2025. These are important signs of recovery, and they should not be understated.  

But the same Board pack shows why the system cannot yet treat elective recovery as structurally stable. The waiting list remains very large, 18-week performance is still below the 2025/26 requirement, provider-level variation remains significant, diagnostics are not keeping pace with demand, and the wider operating environment is financially constrained.  

The core signal is therefore not “elective recovery has been solved”. It is more precise: elective recovery is improving, but the next phase will depend on whether systems can convert short-term activity gains into sustained pathway improvement.

The headline waiting list is moving in the right direction

The most visible positive signal is the reduction in the total elective waiting list. 

NHS England’s Integrated Performance Report shows that the total waiting list stood at 7,247,214 in January 2026. This was down from 7,290,880 in December 2025, a reduction of 43,666 patients, and down from 7,427,669 in January 2025, a year-on-year reduction of 180,455 patients.  

That movement matters because it shows that national and regional recovery actions are producing measurable improvement. NHS England identifies validation incentivisation, enhanced national and regional oversight through tiering, a Q4 performance sprint on additional elective activity, and Getting It Right First Time support as part of the current recovery approach.  

There is also a positive children and young people signal. The under-18 elective waiting list stood at 740,420 for the week ending 22 February 2026, down from 771,515 for the equivalent week in February 2025. This represents a year-on-year reduction of 31,095 patients. NHS England states that it continues to monitor the children and young people elective waiting list across a range of metrics to ensure improvement activity is equitable.  

For patients and families, these reductions are meaningful. Fewer people waiting, and fewer children waiting, means less exposure to delay, uncertainty and deterioration. But the scale of the remaining list means the system is still managing a very large access challenge.

RTT improvementremainsbelow the required trajectory

The second signal is more cautious. Referral to Treatment performance is improving, but not yet enough. 

In January 2026, 61.5% of elective patients were waiting less than 18 weeks for treatment. That was unchanged from December 2025 and up from 58.9% in January 2025. The improvement is real, but NHS England’s own report states that RTT is the main elective performance priority for 2025/26 and 2026/27, and that the 2025/26 requirement is 65%.  

This creates a clear delivery gap. The system is improving year on year, but January 2026 performance remained below the current requirement. That matters because elective recovery cannot be judged only by the size of the waiting list. It must also be judged by how quickly patients are moving through pathways. 

Long waits show a stronger improvement trend. The proportion of elective patients waiting over 52 weeks was 1.87% in January 2026, equivalent to 135,657 patients. This was down from 2.68% in January 2025. NHS England identifies reduction of the longest waits as a continuing priority and a focus of performance oversight with regions and providers in elective tiering.  

The strategic implication is that recovery is uneven across different access measures. The system is reducing the longest waits, but 18-week performance still requires further acceleration. For provider leaders, that means the next phase is not only about doing more activity. It is about improving throughput, clinical prioritisation, pathway discipline and the reliability of conversion from referral to treatment.

Variation is now one of the central risks

The March Board pack shows significant variation across both integrated care boards and acute providers. 

At ICB level, the number of patients on the elective waiting list in January 2026 ranged from 51,772 at the lowest end to 413,539 at the highest end. These figures should not be read as a simple performance league table, because population size, referral patterns, provider configuration and local demand all differ. But the range still shows that elective pressure is not distributed evenly across the NHS.  

Provider-level RTT variation is also material. In January 2026, 18-week RTT performance across acute providers ranged from 97.5% at the highest end to 48.9% at the lowest end. The proportion of patients waiting over 52 weeks also varied across acute trusts, from 0.0% at the lowest end to 7.7% at the highest end.  

This variation is one of the most important signals in the elective recovery data. National averages can show improvement while individual providers and systems remain far from the level of access patients should expect. For patients, this means the experience of elective recovery remains highly dependent on geography and local pathway performance. 

For NHS leaders, variation changes the recovery question. The issue is not only whether national performance improves. It is whether improvement can be made consistent across systems, specialties and providers. 

This is where targeted recovery support becomes important. The system does not need unfocused activity that sits outside local governance. It needs capacity that is clinically prioritised, operationally integrated, properly assured and aligned to provider-level recovery plans.

Diagnosticsremaina constraint on elective recovery 

Elective recovery cannot be separated from diagnostic capacity. 

The March Integrated Performance Report shows that 24.7% of patients were waiting over six weeks for a diagnostic procedure or test in January 2026. This was slightly better than December 2025, but worse than January 2025, when the figure was 22.4%. NHS England attributes this to activity growth failing to keep pace with demand growth, with diagnostic activity growth at 3.3% year to date to December 2025 compared with demand growth of 3.6%.  

This matters because diagnostics sit upstream of treatment. Where diagnostic waits lengthen, elective treatment decisions are delayed. Cancer pathways are also affected. In January 2026, the Faster Diagnosis Standard was 72.8%, while the 62-day combined cancer standard was 68.4% against the 80% planning guidance ambition.  

The diagnostic signal should not be overstretched. This blog is focused on elective recovery, not a full diagnostic deep dive. But it is impossible to assess elective recovery honestly without recognising that diagnostic performance is one of the key constraints on the pathway. 

For leaders, the message is clear: elective recovery cannot be treated as a theatre-only or outpatient-only challenge. It depends on the whole pathway. If diagnostic bottlenecks persist, headline waiting-list reductions may become harder to sustain.

Productivity and financial grip will shape the next phase

The March Board pack also places elective recovery inside a tighter financial and productivity environment. 

The Month 10 finance paper reports that the NHS was broadly in balance nationally, with a £71 million revenue overspend equal to 0.04% of year-to-date allocation. But beneath that national position, systems were overspending by £428 million year to date, with 14 systems formally forecasting year-end overspends. The paper identifies efficiency slippage, workforce costs above planned levels and industrial action cover among the drivers of variance.  

This is highly relevant to elective recovery. In earlier phases of recovery, additional activity could often be framed primarily as a capacity response. In 2026/27, that will not be enough. Capacity will need to demonstrate value, productivity, clinical safety and alignment with system financial plans. 

The Strategy Committee reinforces this direction. It reviewed a Productivity Plan aimed at achieving 2% annual productivity growth, with reducing unwarranted variation identified as the core strategy for baseline productivity gains. The Committee also highlighted expanded day-case surgery, scaled diagnostic models and artificial intelligence as examples of more disruptive innovation to shift the productivity frontier.  

The Committee’s forward project pipeline also includes an Elective Care Strategy, which means elective recovery is moving from an operational recovery issue into a more structured strategic programme.  

The practical implication is that elective support will increasingly be judged against four tests: does it improve access, protect safety, support productivity and fit within financial discipline? 

What this means now

The March Board papers show that elective recovery is improving, but still fragile. 

The waiting list is falling. Long waits are reducing. Children and young people’s waits are lower than a year earlier. RTT performance has improved. These are positive system signals. But they sit alongside a very large residual waiting list, an 18-week performance gap, significant provider variation, diagnostic constraint, cancer pathway pressure and a tighter financial environment.  

For NHS provider and system leaders, the next phase of elective recovery will require more than activity volume. It will require disciplined pathway management, targeted capacity, reliable clinical governance, diagnostic alignment, workforce resilience and productivity improvement. 

For patients, the issue is straightforward: improvement must translate into shorter, safer and more consistent waits. For healthcare workers, the risk is that recovery pressure becomes another layer of operational intensity unless capacity is planned carefully and delivered in a way that supports, rather than destabilises, existing teams. 

The central system implication is this: elective recovery will become secure only when the NHS can reduce waits while also reducing variation, protecting safety and improving productivity. 

That is the standard against which the next phase of recovery should be judged. 

References

NHS England, Integrated Performance Report, March 2026. 
NHS England, Month 10 financial position 2025/26, March 2026. 
NHS England, Board Committee updates – NHS England Strategy Committee, March 2026. 
NHS England, Meeting of the Board of NHS England – agenda, 26 March 2026. 
NHS England, Minutes of a public meeting of the NHS England Board held on Thursday 5 February 2026, published March 2026.